Bestimmung der Pharmakokinetik von Carbapenemen in adipösen Patienten The purpose of this study is to determine the free tissue kinetics of ertapenem and meropenem in fatty tissue and intraperitoneal fluid up to 24 hours after administration of the IMP. Subjects are pat...

• Country None
• organs None
• Specialty None

EUropean Pharmacogenetics of AntiCoagulation Therapy trial The primary endpoint is the percent time within therapeutic INR range 2-3 during 12 weeks following the initiation of coumarin therapy. Our hypothesis is that pharmacogenetic guided dosing will incres...

• Country None
• organs None
• Specialty None

Receptor for Hyaluronan-Mediated Motility (RHAMM [CD168]) peptide vaccination for patients with haematological malignancies: a phaseI/II pilot study Not provided at time of registration

• Country None
• organs None
• Specialty None

Étude ECWM-1 : étude de phase 3 randomisée comparant 2 schémas thérapeutiques, chimiothérapie conventionnelle par dexaméthasone, rituximab et cyclophosphamide (DRC) seule et chimiothérapie conventionnelle DRC associée à du bortezomib chez des patients adultes ayant une maladie de Waldenström (MW). La maladie de Waldenström (MW) est un cancer hématologique rare caractérisé par des cellules lymphocytaires proliférant au niveau de la moelle osseuse entraînant un excès d’une immunoglobuline monoclo...

• Country France
• organs Sang Hématologie - Autres
• Specialty Chimiothérapie, Immunothérapie - Vaccinothérapie

Cytomegalovirus (CMV) peptide vaccine for patients after stem cell transplantation Background and study aims Cytomegovirus CMV) is a common virus belonging to the herpes family. It is spread though bodily fluids and can be oassed on though close contact. Most cases do not cause sym...

• Country None
• organs None
• Specialty None

Effectiveness and Cost-Effectiveness of Needs-Oriented Discharge Planning and Monitoring for High Utilisers of Psychiatric Services Not provided at time of registration

• Country None
• organs None
• Specialty None

Phenprocoumon versus Dabigatran in subjects with atrial fibrillation and left atrial thrombus - a prospective, randomized, controlled, open-label one year follow-up pilot study Phenprocoumon (Marcumar) im Vergleich zu Dabigatran (Pradaxa) bei Patienten mit Vorhofflimmern und einem Thrombus im linken Vorhof - eine prospektive, randomisierte, kontrollierte, offene ein Jahres Follow-Up Pilotstudie To compare Phenprocoumon and Dabigatran for the reduction of left atrial (LA) thrombus size (primary objective) and silent cerebral embolism (secondary objective). Einfluss von Phenprocoumon ver...

• Country None
• organs None
• Specialty None

Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia Eficacia de DRC con o sin Borteomib como primer tratamiento en pacientes con Macroglobulinemia de Waldenström The primary objective of the trial is to evaluate whether the addition of Bortezomib to the combination regimen Dexamethasone/Rituximab/Cyclophosphamide (B-DRC) improves PFS compared to DRC alone. ...

• Country None
• organs None
• Specialty None

Étude ECWM-1 : étude de phase 3 randomisée comparant 2 schémas thérapeutiques, chimiothérapie conventionnelle par dexaméthasone, rituximab et cyclophosphamide (DRC) seule et chimiothérapie conventionnelle DRC associée à du bortezomib chez des patients adultes ayant une maladie de Waldenström (MW). [essai clos aux inclusions] La maladie de Waldenström (MW) est un cancer hématologique rare caractérisé par des cellules lymphocytaires proliférant au niveau de la moelle osseuse entraînant un excès d’une immunoglobuline monoclo...

• Country France
• organs Sang Hématologie - Autres
• Specialty Chimiothérapie, Immunothérapie - Vaccinothérapie

A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II TRIAL OF IBRUTINIB PLUS VENETOCLAX PLUS OBINUTUZUMAB IN PHYSICALLY FIT (CIRS ≤ 6 & NORMAL CREATININE CLEARANCE) OR UNFIT (CIRS >6 OR CREATININE CLEARANCE > 50 ML/MIN) PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH TP53 DELETION (17P-) AND/OR MUTATION (CLL2-GIVE-TRIAL OF THE GCLLSG) The primary objective of the study is to evaluate the efficacy of the GIVe regimen in patients with TP53 deletion (17p-) and/or mutation and previously untreated CLL requiring treatment. For this, th...

• Country None
• organs None
• Specialty None